discuss with a clinician regardless of provider) You want in-person care, frequent lab monitoring, or extensive clinical touch You are using GLP-1s to treat a diabetes indication specifically and need close coordination with primary care You find multi-month prepaid commitments uncomfortable without having seen the product quality first Your state has active enforcement against compounded GLP-1 shipments from out of state A pragmatic first-month approach: 1
In people with obesity, the Wegovy pill and the injection produce similar weight loss results
There were no deaths during the trial, and no clinically diagnosed cases of pancreatitis were reported
Individual variation is significant
At this time there is no conclusive evidence that GLP-1 medications directly damage the microbiome, but changes in appetite, meal size, and food variety can influence microbial diversity over time
Research-Based Cycle Protocols Short-Term Assessment (4-8 Weeks): An initial 4-8 week cycle allows evaluation of individual response, tolerance assessment, and metabolic changes without extended commitment